标签归档：mapatumumab

Mapatumumab (Synonyms: 马帕木单抗; HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Mapatumumab  (Synonyms: 马帕木单抗; HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody)

Mapatumumab (HGS-ETR1) 是靶向肿瘤坏死因子相关凋亡诱导配体受体 1 (TRAIL-R1) 的全人 IgG1 激动性单克隆抗体。Mapatumumab 可用于肿瘤的研究。

  • Mapatumumab (Synonyms: 马帕木单抗; HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody)
  • Mapatumumab (Synonyms: 马帕木单抗; HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody)

  1. Mapatumumab (Synonyms: 马帕木单抗; HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody)
  2. Mapatumumab (Synonyms: 马帕木单抗; HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody)

CAS No. : 658052-09-6

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Mapatumumab 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer[1].

同型

Human IgG1 nd
推荐同型对照抗体

Human IgG1 kappa, Isotype Control
种属

Human
体外研究
(In Vitro)

Mapatumumab (0.01-100 μg/mL; 4 h) shows no growth inhibition to Pediatric Preclinical Testing Program (PPTP) cell lines[1].
Mapatumumab (1-100 ng/mL; 24 h) shows significant potentiation of cytotoxicity and synergy when combined with (epirubicin) EPI for bladder cancer cells[2].
Mapatumumab (100 ng/mL; 12 h) induces significant cell apoptosis of T24, 253J and J82 cells with the combination of EPI (1 μg/mL)[2].
Mapatumumab (100 ng/mL; 6-24 h) significantly activates caspase-8, -9 and -3 with the combination of EPI (1 μg/mL)[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Mapatumumab 相关抗体:
体内研究
(In Vivo)

Mapatumumab (10 mg/kg; i.p. for three times) controls tumor growth when combined with irradiation[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Colo205-xenograft–bearing NMRI (nu/nu) nude mice[3]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8
Result: Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1–5) showed a pronounced tumor regrowth-delay.

Clinical Trial

分子量

151.89 (kDa)

CAS 号

658052-09-6
中文名称

马帕木单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Mapatumumab (Synonyms: 马帕木单抗; HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody)
    Human IgG1 nd
纯度 & 产品资料
Data Sheet (516 KB) 抗体抑制剂使用指南 (1152 KB)

参考文献

  • [1]. Smith MA, et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54(2):307-10.

    [2]. Ahmed SM, et al. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. Oncol Rep. 2015 Feb;33(2):566-72.  [Content Brief]

    [3]. Marini P, et al. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):198-202.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务